Precursor Condition
Monoclonal Gammopathy of Undetermined Significance
CI-CAN-00006048MGUSExplore in graph →
HematologicPrecursor13 active trials
Loading cancer entity…
Loading cancer entity…
Precursor Condition
CI-CAN-00006048MGUSExplore in graph →
Clinical trials
59 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01079429 | Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM.(GENOMGUS) | terminated | — | 1,200 | Rennes University HospitalOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT01109407 | Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM) | terminated | — | 225 | National Cancer Institute (NCI)NIH | 1 |
| Mar 8, 2021 |
| clinicaltrials |
| NCT00588822 | Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance | terminated | Phase 2 | 21 | Mayo ClinicOTHER | 1 | May 6, 2014 | clinicaltrials |
| NCT00899353 | Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) | terminated | Phase 2 | 16 | Marshall UniversityOTHER | 1 | Dec 12, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Apr 15, 2021source: clinicaltrials